Plain-English translation of NCT07154082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether Apatinib Mesylate combined with another medication called Camrelizumab, given alongside a procedure called TACE (a type of targeted liver treatment), can help shrink liver tumors before surgery. The goal is to make tumors smaller so that surgery is more successful and reduces the risk that cancer will come back after the operation.
Current treatments for liver cancer at this stage don't always prevent the cancer from returning after surgery. Doctors are exploring whether this medication combination might work better by reducing tumor size before surgery and lowering the risk of recurrence.
You likely qualify if…
You likely don't qualify if…
You would first receive TACE treatment, a minimally invasive procedure done in a hospital setting. About one week later, once you've recovered from the procedure, you would begin taking the medication combination: an injection given every two weeks for 8 weeks, and a daily pill taken by mouth for 2 months. You would have regular clinic visits to monitor how you're doing, and imaging tests to see how the tumor is responding. After treatment, you would have surgery to remove the tumor, followed by ongoing follow-up visits to watch for any signs of cancer returning.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
China